| Entry |
|
|---|
| Name |
Clopenthixol (USAN) |
|---|
| Formula |
C22H25ClN2OS
|
|---|
| Exact mass |
400.1376
|
|---|
| Mol weight |
400.9647
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG01478 Dopamine antagonist
|
|---|
| Remark |
|
|---|
| Efficacy |
Antipsychotic, Dopamine receptor antagonist |
|---|
| Comment |
Thioxanthene derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05A ANTIPSYCHOTICS
N05AF Thioxanthene derivatives
N05AF02 Clopenthixol
D02613 Clopenthixol (USAN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01478 Dopamine antagonist
D02613 Clopenthixol
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD1
D02613 Clopenthixol (USAN)
DRD2
D02613 Clopenthixol (USAN)
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 27
1 C8x C 11.0067 -21.8635
2 C8x C 11.0067 -23.2652
3 C8x C 12.2683 -23.9661
4 C8x C 12.2683 -21.1627
5 C8y C 13.3896 -21.8635
6 C8y C 13.3896 -23.2652
7 S2x S 14.6510 -23.9661
8 C8y C 14.6510 -21.1627
9 C8y C 15.8425 -21.8635
10 C8y C 15.8425 -23.2652
11 C8x C 17.0338 -23.9661
12 C8x C 18.2953 -23.2652
13 C8y C 18.2953 -21.8635
14 C8x C 17.0338 -21.1627
15 C2b C 14.6510 -19.7611
16 C1b C 15.8654 -19.0609
17 C1b C 15.8654 -17.6593
18 N1y N 17.0622 -16.9681
19 C1x C 18.2503 -17.6540
20 C1x C 19.4642 -16.9532
21 N1y N 19.4641 -15.5515
22 C1x C 18.2760 -14.8656
23 C1x C 17.0622 -15.5664
24 C1b C 20.7006 -14.8553
25 C1b C 21.9144 -15.5561
26 O1a O 23.1283 -14.8553
27 X Cl 19.5034 -21.1527
BOND 30
1 8 5 1
2 1 2 1
3 2 3 2
4 3 6 1
5 9 10 2
6 10 11 1
7 11 12 2
8 12 13 1
9 13 14 2
10 14 9 1
11 5 4 1
12 8 15 2
13 4 1 2
14 5 6 2
15 6 7 1
16 7 10 1
17 9 8 1
18 15 16 1
19 16 17 1
20 17 18 1
21 18 19 1
22 19 20 1
23 20 21 1
24 21 22 1
25 22 23 1
26 18 23 1
27 21 24 1
28 24 25 1
29 25 26 1
30 13 27 1
|
|---|
